These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19715403)

  • 1. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
    Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
    Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
    Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
    Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
    Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
    Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
    Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
    Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
    Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
    Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
    Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
    Wollmann G; Paglino JC; Maloney PR; Ahmadi SA; van den Pol AN
    Virology; 2015 Jan; 475():1-14. PubMed ID: 25462341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
    Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
    J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell Cycle Arrest in G
    Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.
    Kurisetty VV; Heiber J; Myers R; Pereira GS; Goodwin JW; Federspiel MJ; Russell SJ; Peng KW; Barber G; Merchan JR
    Head Neck; 2014 Nov; 36(11):1619-27. PubMed ID: 24115092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
    Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
    J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
    Paglino JC; van den Pol AN
    J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
    Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
    Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
    Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
    Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
    Obuchi M; Fernandez M; Barber GN
    J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
    Kelly KJ; Woo Y; Brader P; Yu Z; Riedl C; Lin SF; Chen N; Yu YA; Rusch VW; Szalay AA; Fong Y
    Hum Gene Ther; 2008 Aug; 19(8):774-82. PubMed ID: 18754710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.